Envestnet Portfolio Solutions
LGND icon

Envestnet Portfolio Solutions’s Ligand Pharmaceuticals LGND Stock Holding History

Envestnet Portfolio Solutions’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,407
Closed -$266K – 1416
2025
Q4 		$266K Sell
1,407
-153
-10% -$29.4K ﹤0.01% 1348
2025
Q3 		$276K Buy
+1,560
New +$232K ﹤0.01% 1289

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Envestnet Portfolio Solutions's LGND Position: Q1 2026 in Review

Envestnet Portfolio Solutions sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 1,407 shares — an estimated $266K sold.

Envestnet Portfolio Solutions first reported a position in LGND in Q3 2025 and held it in 2 quarters. The position peaked at $276K in Q3 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Envestnet Portfolio Solutions reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Envestnet Portfolio Solutions sold 1,407 Ligand Pharmaceuticals shares in Q1 2026, an estimated $266K.
  • Envestnet Portfolio Solutions first reported a position in Ligand Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Envestnet Portfolio Solutions's Ligand Pharmaceuticals position peaked at $276K in Q3 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Envestnet Portfolio Solutions's 13F filing for Q1 2026, filed 29 Apr 2026.